17 Biotechnology Stocks to Buy Now

This week, 17 Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

United Therapeutics Corporation (UTHR) is seeing ratings go up from a C last week to a B this week. United Therapeutics Corporation is a biotechnology company that develops and commercializes therapeutic products for patients with chronic and life-threatening diseases. The company also gets A’s in operating margin growth, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of UTHR stock.

Gilead Sciences, Inc. (GILD) gets a higher grade this week, advancing from a C last week to a B. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The company also gets A’s in sales growth, earnings growth, earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of GILD stock.

This week, Ultragenyx Pharmaceutical, Inc.’s (RARE) ratings are up from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of RARE stock.

AbbVie, Inc.’s (ABBV) ratings are looking better this week, moving up to a B from last week’s C. AbbVie, Inc. a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. The company also gets A’s in earnings growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of ABBV stock.

TESARO, Inc. (TSRO) earns a B this week, jumping up from last week’s grade of C. TESARO, Inc. develops and commercializes cancer therapeutics and supportive care products. For more information, get Portfolio Grader’s complete analysis of TSRO stock.

Loxo Oncology Inc (LOXO) shows solid improvement this week. The company’s rating rises from a B to a A. For more information, get Portfolio Grader’s complete analysis of LOXO stock.

This is a strong week for Ascendis Pharma A/S (ASND). The company’s rating climbs to B from the previous week’s C. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of ASND stock.

Cellular Biomedicine Group, Inc. (CBMG) improves from a C to a B rating this week. For more information, get Portfolio Grader’s complete analysis of CBMG stock.

Atara Biotherapeutics Inc (ATRA) boosts its rating from a C to a B this week. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of ATRA stock.

This week, La Jolla Pharmaceutical Company (LJPC) pushes up from a C to a B rating. For more information, get Portfolio Grader’s complete analysis of LJPC stock.

The rating of Enzymotec Ltd. (ENZY) moves up this week, rising from a B to a A. The company also gets A’s in sales growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ENZY stock.

This week, Sinovac Biotech Ltd.’s (SVA) ratings are up from a B last week to a A. Sinovac Biotech Ltd. researches, develops, manufactures, and markets various vaccines, including flu vaccines and vaccines for Hepatitis A. The company also gets A’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of SVA stock.

Tobira Therapeutics, Inc. (TBRA) shows solid improvement this week. The company’s rating rises from a C to a B. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of TBRA stock.

Advaxis, Inc. (ADXS) improves from a C to a B rating this week. For more information, get Portfolio Grader’s complete analysis of ADXS stock.

The rating of Inovio Pharmaceuticals, Inc. (INO) moves up this week, rising from a C to a B. Inovio Pharmaceuticals, Inc. engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of INO stock.

Amicus Therapeutics, Inc. (FOLD) is seeing ratings go up from a C last week to a B this week. Amicus Therapeutics, Inc. is a biopharmaceutical company which is focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones. For more information, get Portfolio Grader’s complete analysis of FOLD stock.

Trovagene, Inc. (TROV) earns a B this week, jumping up from last week’s grade of C. Trovagene, Inc. is developing a non-invasive testing technology using transrenal nucleic acid (TrNA) markers for infectious diseases, prenatal testing, early detection of cancer, and monitoring of organ and cell transplantation. The company also gets A’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of TROV stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/02/17-biotechnology-stocks-to-buy-now-3/.

©2021 InvestorPlace Media, LLC